12 June: Eli Lilly and AstraZeneca halt AMARANTH and DAYBREAK-ALZ Phase 3 studies

On 12 June, the pharmaceutical companies Eli Lilly and AstraZeneca announced the end of two global Phase 3 trials of the experimental drug lanabecestat, which is an oral beta secretase cleaving enzyme (BACE) inhibitor.

Read more »
Rate: 12345 (0) | Facebook Twitter
 
19 June: Portuguese Health Ministry launches National Health Strategy for Dementia

On 19 June, the Portuguese Health Ministry launched the Health Strategy for Dementia.  The Strategy states the principles of care for people with dementia, criteria for prevention, early detection, availability of clinical and comprehensive diagnosis, therapeutic intervention at primary, hospital and specialised care, clarifying the care pathway based on ethical principles, proximity, availability, equity and continuity.

Read more »
Rate: 12345 (0) | Facebook Twitter
 
26 June: Alzheimer Europe calls on French health authorities to continue reimbursing anti-Alzheimer’s medicines

At its meeting of 26 June 2018, the Alzheimer Europe Board condemned the recent decision of the French government to exclude current medicines licensed for the treatment of Alzheimer’s disease from the reimbursement system. Alzheimer Europe and its members organisations fully support the campaign and on-line petition of France Alzheimer which calls for the continued reimbursement of these medicines.

Read more »
Rate: 12345 (0) | Facebook Twitter
 
26 June: Alzheimer Europe survey highlights significant barriers to timely diagnosis

In a report presented today at a lunch debate hosted by MEPs Olga Sehnalová (Czech Republic) and Sirpa Pietikäinen (Finland) in the European Parliament, Alzheimer Europe highlighted significant barriers to timely diagnosis across Europe.

Read more »
Rate: 12345 (1) | Facebook Twitter